Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620800 · ClinicalTrials.gov registry record · Phase 1
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
A Phase 1 study of Metastatic Pancreas Adenocarcinoma, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 7
- Study locations
NCT02620800 is a Phase 1 study of Metastatic Pancreas Adenocarcinoma that has completed, run by Celgene. The registered enrollment target is 12 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT02620800, a Phase 1 study of Metastatic Pancreas Adenocarcinoma, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic pancreatic adenocarcinoma.
Conditions Studied
Interventions
- DRUG nab-paclitaxel
- DRUG bevacizumab
- DRUG oxaliplatin
- DRUG 5FU
- DRUG calcium leucovorin
Study Locations (7)
Michigan
- University of Michigan - Ann Arbor
- Karmanos Cancer Center Wayne State University - Detroit
Illinois
- Northwestern University - Chicago
Massachusetts
- Tufts - New England Medical Center - Boston
New York
- Cornell University Weill Medical College - New York
South Carolina
- Gibbs Cancer Center and Research Institute - Spartanburg
Washington
- Virginia Mason Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-01-18 |
| Est. Completion | 2018-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02620800
The ClinicalTrials.gov registry entry for NCT02620800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Pancreas Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which nab-paclitaxel is the first listed.
NCT02620800 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Michigan, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02620800 about?
NCT02620800 is a clinical study titled "Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer". The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic pancreatic adenocarcinoma.
What is the current status of trial NCT02620800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-01-18. Estimated completion is 2018-10-29.
What conditions does trial NCT02620800 study?
This clinical trial studies the following conditions: Metastatic Pancreas Adenocarcinoma.
What interventions are being tested in trial NCT02620800?
The interventions under investigation include: nab-paclitaxel (DRUG), bevacizumab (DRUG), oxaliplatin (DRUG), 5FU (DRUG), calcium leucovorin (DRUG).
Who is sponsoring clinical trial NCT02620800?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02620800 being conducted?
This trial has 7 study locations across Illinois, Massachusetts, Michigan, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.